Amedisys, Inc. (NASDAQ:AMED) Shares Acquired by Barclays PLC

Barclays PLC lifted its holdings in Amedisys, Inc. (NASDAQ:AMED) by 49.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,529 shares of the health services provider’s stock after purchasing an additional 5,142 shares during the period. Barclays PLC’s holdings in Amedisys were worth $1,500,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. KBC Group NV purchased a new position in shares of Amedisys in the 3rd quarter valued at about $63,000. Signaturefd LLC increased its stake in shares of Amedisys by 20.9% in the 3rd quarter. Signaturefd LLC now owns 1,367 shares of the health services provider’s stock valued at $132,000 after purchasing an additional 236 shares in the last quarter. CWM LLC increased its stake in shares of Amedisys by 14.5% in the 3rd quarter. CWM LLC now owns 2,190 shares of the health services provider’s stock valued at $211,000 after purchasing an additional 277 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new position in shares of Amedisys in the 3rd quarter valued at about $243,000. Finally, Intech Investment Management LLC purchased a new stake in Amedisys during the 2nd quarter worth approximately $280,000. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Amedisys Price Performance

NASDAQ:AMED opened at $91.90 on Monday. Amedisys, Inc. has a 12 month low of $82.15 and a 12 month high of $98.95. The stock has a 50 day moving average of $89.49 and a two-hundred day moving average of $94.45. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. The firm has a market cap of $3.01 billion, a P/E ratio of 36.47, a price-to-earnings-growth ratio of 1.84 and a beta of 0.72.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, November 6th. The health services provider reported $1.00 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.19). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm had revenue of $587.67 million for the quarter, compared to analysts’ expectations of $586.75 million. During the same quarter last year, the firm posted $0.98 earnings per share. Amedisys’s quarterly revenue was up 5.7% on a year-over-year basis. On average, analysts expect that Amedisys, Inc. will post 4.45 earnings per share for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.